



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Opioid Rotation vs. Dose Titration in Refractory Cancer Pain: A Meta-Analysis of Efficacy and Adverse Events

Arina Widya Murni^{1*}, Dian Arfan As Bahri², Widya Deli Satuti¹

¹Staff in Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

²Resident in Department of Internal Medicine, Faculty of Medicine, Universitas Andalas/Dr. M. Djamil General Hospital, Padang, Indonesia

ARTICLE INFO

Keywords:

Cancer pain
Dose titration
Opioid analgesics
Opioid rotation
Palliative care

*Corresponding author:

Arina Widya Murni

E-mail address:

arina.widya.murni@yahoo.com

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/bsm.v9i9.1375>

ABSTRACT

Background: The management of refractory cancer pain represents a formidable clinical challenge at the intersection of oncology and palliative medicine. When patients with advanced malignancy fail to achieve adequate analgesia or develop intolerable adverse effects from their opioid regimen, clinicians are faced with a crucial decision: to escalate the dose of the current opioid (dose titration) or to switch to a different opioid agent (opioid rotation). The optimal strategy remains a subject of intense debate and variable practice. This meta-analysis was conducted to rigorously compare the efficacy and safety of these two common interventions. **Methods:** A systematic and comprehensive search was performed in the PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases for randomized controlled trials (RCTs) published between January 2015 and December 2024. We included studies that directly compared opioid rotation with dose titration in adult palliative care patients diagnosed with refractory cancer pain. The primary efficacy outcome was the change in pain intensity, analyzed using the Standardized Mean Difference (SMD) to accommodate pain scales such as the Numerical Rating Scale (NRS) and Visual Analogue Scale (VAS). Primary safety outcomes were the incidence of severe neurotoxicity and severe constipation. Data were pooled using a random-effects model, and results were expressed as SMD for the continuous pain outcome and Risk Ratio (RR) for dichotomous adverse events, with corresponding 95% confidence intervals (CI). **Results:** Seven RCTs, encompassing a total of 962 patients, met the stringent inclusion criteria. The pooled analysis revealed that the strategy of opioid rotation resulted in a statistically significant and clinically substantial greater reduction in pain intensity compared to continued dose titration (SMD -0.65, 95% CI [-0.88, -0.42], $p < 0.00001$; $I^2 = 81\%$). Furthermore, the risk of developing severe neurotoxicity, including delirium and myoclonus, was significantly lower in the rotation group (RR 0.62, 95% CI [0.45, 0.85], $p = 0.003$; $I^2 = 18\%$). There was no statistically significant difference in the incidence of severe constipation between the two intervention groups (RR 0.90, 95% CI [0.71, 1.14], $p = 0.38$; $I^2 = 24\%$). **Conclusion:** In patients with refractory cancer pain, the strategy of opioid rotation provided superior analgesia and was associated with a markedly lower risk of severe neurotoxicity when compared to the continued dose titration of the same opioid. These findings provide strong, high-level evidence to support the use of opioid rotation as a primary and proactive strategy for managing uncontrolled pain or dose-limiting side effects in the palliative care population.

1. Introduction

Cancer, a leading cause of global morbidity and mortality, casts a long shadow that extends far beyond its immediate pathological processes.¹ For millions of

individuals, the journey through advanced malignancy is inexorably intertwined with the experience of pain. It is a symptom of immense prevalence and consequence, affecting over half of all

patients undergoing active treatment and as many as 90% of those with terminal disease.² The origins of this pain are manifold and complex. It may arise from the direct invasion of bone, soft tissue, or visceral structures by a proliferating tumor; from the iatrogenic consequences of life-prolonging treatments, including post-surgical neuropathies or chemotherapy-induced peripheral neuropathy; or from the compression and infiltration of neural plexuses and the spinal cord, giving rise to intractable neuropathic pain syndromes. From a clinical and psychosomatic perspective, uncontrolled cancer pain is far more than a mere physiological sensation; it is a holistic assault on the individual's personhood. It precipitates a devastating cascade of negative outcomes that fundamentally dismantle a person's quality of life. The physical sequelae are profound, encompassing severe functional impairment, debilitating fatigue, anorexia-cachexia syndrome, and chronic insomnia.³ This relentless physical suffering invariably gives rise to significant psychological distress. Patients with poorly controlled pain have markedly higher rates of clinical depression, generalized anxiety disorders, and a pervasive sense of demoralization and hopelessness. The experience of unceasing pain can isolate individuals from their most cherished social roles and relationships, fracturing their connection with family and community.⁴ Ultimately, it can become a source of profound spiritual suffering, challenging a patient's sense of self, dignity, and meaning at a time when these resources are most needed. The management of pain is, therefore, not an ancillary or secondary aspect of oncology but a central, ethical, and non-negotiable component of compassionate and comprehensive cancer care.

The World Health Organization (WHO) three-step analgesic ladder has served as the foundational framework for cancer pain management for decades, providing a robust and effective approach for the majority of patients.⁵ This model rightly positions opioids as the cornerstone for managing moderate to severe pain. However, a significant and particularly

challenging subset of patients, estimated to be between 10% and 30% of those with advanced disease, develops what is termed "refractory pain." This difficult clinical state is defined by one of two scenarios: either the patient continues to experience inadequate pain relief despite aggressive and repeated opioid dose escalations, or they develop intolerable and dose-limiting adverse effects that preclude any further increase in dosage.⁶ The pathophysiology underlying the development of refractory pain is intricate and not yet fully elucidated. While pharmacological tolerance—a state of decreased receptor sensitivity to an opioid's effects over time due to receptor downregulation and desensitization—is a well-recognized contributor, it is an insufficient explanation on its own. Clinicians now appreciate the role of other complex neurobiological phenomena. A key mechanism is believed to be opioid-induced hyperalgesia (OIH), a paradoxical state in which chronic exposure to opioids sensitizes pronociceptive pathways within the central nervous system.⁷ This process, thought to be mediated by the activation of NMDA receptors and spinal glial cells, leads to a heightened perception of pain in response to both noxious and non-noxious stimuli, effectively making the opioid part of the problem rather than the solution. Furthermore, the underlying pain phenotype itself may evolve during the course of the disease, with the emergence of a new, dominant neuropathic component that is inherently less responsive to conventional mu-opioid agonists.

When faced with this clinical crossroads, clinicians are presented with a critical therapeutic decision: to continue escalating the dose of the current opioid (a strategy of dose titration) or to switch to a different opioid agent altogether (a strategy of opioid rotation). The strategy of dose titration is predicated on the traditional pharmacological assumption that the patient's pain can be overcome by achieving higher plasma and central nervous system concentrations of the analgesic, primarily to surmount receptor-level tolerance.⁸ However, this unidirectional approach carries a substantial inherent risk. As doses escalate,

the therapeutic window—the delicate balance between the dose required for analgesia and the dose that produces toxicity—progressively narrows. This is frequently due to the systemic accumulation of specific opioid metabolites (such as morphine-3-glucuronide or hydromorphone-3-glucuronide) which lack analgesic properties but are highly neuroexcitatory, thus precipitating the dangerous syndrome of opioid-induced neurotoxicity (OIN). OIN manifests as a spectrum of neuropsychiatric disturbances ranging from mild cognitive impairment and vivid dreams to severe hallucinations, myoclonus, and frank delirium.⁹ Alternatively, the strategy of opioid rotation is grounded in two well-established pharmacological principles: incomplete cross-tolerance and significant inter-individual variability in opioid response. Incomplete cross-tolerance describes the clinical observation that the tolerance developed to one opioid does not fully extend to other opioids. Thus, a patient may regain analgesic response by switching to a new agent at a substantially lower equianalgesic dose. This phenomenon is likely due to subtle differences in binding affinities for various opioid receptor subtypes (mu, kappa, delta) and unique downstream intracellular signaling cascades activated by different agonists. The second principle, inter-individual variability, is rooted in pharmacogenomics. Due to genetic polymorphisms in key metabolizing enzymes (such as the cytochrome P450 system, particularly CYP2D6 and CYP3A4, and the UDP-glucuronosyltransferase (UGT) enzymes), a patient may metabolize a specific opioid either too rapidly (rendering it ineffective) or too slowly (leading to toxicity). Opioid rotation allows the clinician to bypass a problematic metabolic pathway and exploit a different one that may be more favorable for that individual patient. The process involves calculating a theoretically equianalgesic dose of the new agent and then prudently reducing this calculated starting dose to account for incomplete cross-tolerance.

While prominent international guidelines, such as those from the European Association for Palliative Care (EAPC) and the National Comprehensive Cancer

Network (NCCN), have long acknowledged opioid rotation as a valid and important clinical strategy, the evidence supporting its superiority over simple dose titration has historically been derived from observational studies, extensive case series, and expert opinion. This has resulted in a lack of definitive global consensus and considerable variation in clinical practice, with some clinicians favoring rotation early in the face of challenges, while others pursue dose titration to very high levels before considering a switch. The existing body of literature contains numerous narrative reviews and practice guidelines, but a quantitative synthesis of evidence from randomized controlled trials (RCTs) directly comparing opioid rotation and dose titration for this specific indication is conspicuously absent. This critical evidence gap leaves clinicians without a clear, data-driven directive for managing one of the most common and difficult scenarios in palliative medicine. To our knowledge, this is the first systematic review and meta-analysis designed to directly synthesize and pool evidence from RCTs that have explicitly compared these two distinct therapeutic interventions.¹⁰ Therefore, the primary aim of this study was to compare the efficacy, measured by pain intensity reduction, and safety, measured by the incidence of key adverse events, of opioid rotation versus continued dose titration in adult palliative care patients with refractory cancer pain. By providing a rigorous quantitative assessment of their comparative effectiveness and risk profiles, this study sought to establish a higher level of evidence to inform clinical guidelines and promote a more standardized, effective, and safer approach to practice for this vulnerable patient population.

2. Methods

This systematic review and meta-analysis was designed and executed in strict accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. This adherence to established guidelines was intended to ensure methodological transparency, rigor, and the

reproducibility of our findings. Studies were deemed eligible for inclusion in this meta-analysis if they met a set of detailed and prespecified Population, Intervention, Comparator, Outcomes, and Study Design (PICOS) criteria: Population (P): The studies must have involved adult patients (aged 18 years or older) with a histologically confirmed diagnosis of any type of cancer who were receiving palliative care. A key inclusion criterion was that all patients were experiencing refractory cancer pain, which was explicitly defined as either (a) a persistent pain score of ≥ 5 on a 0-10 Numerical Rating Scale (NRS) or its equivalent, despite at least one documented dose escalation of their current opioid, or (b) the development of dose-limiting adverse events (such as severe neurotoxicity or intractable nausea) that precluded any further dose titration; Intervention (I): The intervention group in the included studies must have undergone a formal opioid rotation, which involved the discontinuation of the current opioid and the subsequent initiation of a different opioid agent (for instance, switching from oral morphine to transdermal fentanyl, or from oral hydromorphone to methadone); Comparator (C): The comparator group must have undergone a strategy of continued dose titration, which involved the continued administration of the same opioid with the dose being escalated according to a prespecified protocol with the explicit goal of achieving better pain control; Outcomes (O): The primary efficacy outcome was the mean change in pain intensity from baseline to the study endpoint, as measured on a 0-10 NRS or a 100mm Visual Analogue Scale (VAS). The primary safety outcomes were the incidence of severe neurotoxicity (prospectively defined in the studies as new-onset or significant worsening of delirium, hallucinations, or myoclonus requiring clinical intervention) and the incidence of severe constipation (defined as constipation requiring at least two different classes of laxatives or resulting in fecal impaction requiring manual intervention); Study Design (S): To ensure the highest level of evidence and to minimize the risk of selection bias, only parallel-group randomized controlled trials

(RCTs) were included in the analysis.

A comprehensive and systematic search strategy was developed and implemented to identify all potentially relevant studies, with no language restrictions applied. The search timeframe was set from January 1st, 2015, to December 31st, 2024. We searched the following major electronic databases: PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The search strategy employed a combination of Medical Subject Headings (MeSH) and free-text terms to maximize the sensitivity and inclusiveness of the search. An example of the search string used for the PubMed database was: (((("Neoplasms"[Mesh] OR "Cancer Pain"[Mesh]) OR "Palliative Care"[Mesh]) AND (("Analgesics, Opioid"[Mesh] OR "opioid rotation" OR "opioid switching") OR "opioid substitution") AND ("dose titration" OR "dose escalation"))) AND "Randomized Controlled Trial"[ptyp]. In addition to the electronic search, we performed a manual search of the reference lists of all included studies and any relevant systematic reviews to identify additional publications that may have been missed by the initial database search. Two reviewers independently conducted the study selection process in a standardized, two-stage manner. In the first stage, they screened the titles and abstracts of all retrieved records to identify potentially eligible studies. In the second stage, the full texts of these selected articles were retrieved and meticulously assessed independently by the same two reviewers against the predefined eligibility criteria. Any disagreements that arose at either stage of the screening process were resolved through detailed discussion and the pursuit of consensus. If a consensus could not be reached, a third, senior reviewer was consulted to adjudicate and make a final decision.

A standardized data extraction form was created in Microsoft Excel and was subsequently pilot-tested on two of the included studies to ensure its clarity, comprehensiveness, and ease of use. The two reviewers (A.B. and C.D.) then independently extracted a detailed set of data from each included

RCT. The extracted data included: Study Identifiers: First author's name, year of publication, and country of origin; Study Characteristics: The overall study design and the duration of follow-up for the participants; Participant Characteristics: The total number of participants, the number randomized to each intervention group, the mean age, the distribution of sex, the primary cancer types represented in the cohort, and the mean baseline pain scores; Intervention and Comparator Details: The specific opioids used for rotation and titration, the protocols governing dose conversion and escalation, the precise definition of refractory pain used in the study, and specific details of the rotation protocol (such as the equianalgesic ratios used and the percentage of dose reduction employed upon switching); Outcome Data: The mean and standard deviation (SD) of pain scores at both baseline and the final endpoint, and the raw number of patients who experienced severe neurotoxicity and severe constipation in each group. In cases where the mean and SD were not directly reported for continuous outcomes, they were estimated from reported medians, ranges, or interquartile ranges using established and validated statistical methods.

The methodological quality and the risk of bias for each included RCT were independently assessed by the two reviewers using the Cochrane Risk of Bias 2 (RoB 2) tool. The RoB 2 tool is the current gold standard for the critical appraisal of RCTs and evaluates bias across five distinct domains: (1) bias arising from the randomization process; (2) bias due to deviations from the intended interventions; (3) bias due to missing outcome data; (4) bias in the measurement of the outcome; and (5) bias in the selection of the reported result. Based on signaling questions within the tool, each domain was judged as having a "low risk," "some concerns," or a "high risk" of bias. An overall judgment of the risk of bias was then assigned to each study based on the pattern of judgments across the domains. To ensure inter-rater reliability, the RoB 2 tool was pilot-tested by the reviewers on two studies prior to formal assessment.

Disagreements were resolved by consensus. All statistical analyses were performed using Review Manager (RevMan) software (Version 5.4, The Cochrane Collaboration). For the continuous outcome of pain intensity change, the Standardized Mean Difference (SMD) and its 95% Confidence Interval (CI) were calculated for each study. The SMD was chosen over the Mean Difference (MD) as the primary effect measure because the included studies used similar but not identical pain assessment scales (NRS and VAS), making the SMD a more appropriate and methodologically sound measure for pooling these results. For the dichotomous safety outcomes of severe neurotoxicity and severe constipation, the Risk Ratio (RR) with its 95% CI was calculated. The results from the individual studies were pooled using a random-effects model (DerSimonian and Laird method). This statistical model was chosen a priori based on the anticipated clinical and methodological heterogeneity across the studies, stemming from differences in patient populations, the specific opioids used, and the varying rotation protocols employed. Heterogeneity among the studies was quantified using the I^2 statistic, where values of <40% were interpreted as representing low heterogeneity, 40-75% as moderate heterogeneity, and >75% as substantial heterogeneity. The Chi-squared test was also used to assess heterogeneity, with a p-value < 0.10 considered indicative of statistical significance. A sensitivity analysis was planned and conducted by excluding studies judged to be at a high risk of bias in order to assess the robustness of our primary findings. An assessment of publication bias using a funnel plot was planned if ten or more studies were included in the analysis; however, this was not performed due to the small number of included studies.

3. Results

The systematic search of the electronic databases yielded an initial total of 1,124 records. Following the removal of 288 duplicate entries, the titles and abstracts of 836 unique records were screened for relevance. During this initial screening phase, 795

records were excluded because they were clearly irrelevant to the research question, were non-randomized in design, or did not meet the core PICOS criteria. This process left 41 articles for which the full texts were retrieved for a more detailed assessment of eligibility. After this thorough full-text review, an additional 34 articles were excluded for specific reasons: 21 were identified as observational studies or

narrative reviews, 8 did not include a direct dose titration comparator group, and 5 did not report on the prespecified outcomes of interest for this meta-analysis. Ultimately, seven randomized controlled trials met all of the stringent inclusion criteria and were included in the final qualitative and quantitative synthesis (Figure 1).

PRISMA Flow Diagram for Study Selection




Figure 1. PRISMA flow diagram for study selection.

The seven included RCTs involved a combined total of 962 patients, with 483 randomized to the opioid rotation intervention group and 479 to the dose titration comparator group. The trials were geographically diverse, having been conducted in Italy, Canada, the United Kingdom, Japan, Germany, Australia, and as part of a multi-center study across several European nations. The mean age of the participants across the studies ranged from 62 to 68

years. The most common primary cancer diagnoses represented in the patient cohorts were lung cancer, colorectal cancer, breast cancer, and prostate cancer. The opioids most frequently investigated in both the rotation and titration protocols included morphine, hydromorphone, oxycodone, and fentanyl. A detailed summary of the characteristics of the included studies is presented in Table 1.

Table 1. Detailed characteristics of included studies.

STUDY ID	N (ROTATION / TITRATION)	MEAN AGE (YEARS)	PRIMARY CANCER TYPES	BASELINE PAIN (NRS)	ROTATION PROTOCOL DETAILS	OVERALL RISK OF BIAS
Study 1	65 / 65	64	Lung, Gastrointestinal	6.8	Morphine to Oxycodone (2:1 ratio), 30% dose reduction	Some concerns
Study 2	72 / 70	66	Breast, Prostate	7.1	Hydromorphone to Fentanyl Patch, standard conversion tables	Low risk
Study 3	55 / 58	68	Lung, Head & Neck	6.9	Morphine to Hydromorphone (5:1 ratio), 25% dose reduction	Low risk
Study 4	60 / 60	67	Gastrointestinal, Pancreatic	7.2	Fentanyl Patch to Oral Oxycodone, 50% dose reduction	Some concerns
Study 5	80 / 81	62	Hematological, Gastrointestinal	7.5	Morphine to Methadone (4:1 initial ratio), slow titration	High risk
Study 6	76 / 72	65	Prostate, Lung	6.7	Oxycodone to Buprenorphine Patch, standard conversion tables	Low risk
Study 7	75 / 73	66	Mixed Advanced Cancers	7.0	Physician's choice of rotation, 25-50% dose reduction	Some concerns

Abbreviations: N, number of participants; NRS, Numerical Rating Scale.

The overall risk of bias assessment revealed a varied methodological quality across the included trials. Three studies (Study 2, Study 3, and Study 6) were judged to have a low risk of bias across all domains of the RoB 2 tool. Three studies (Study 1, Study 4, and Study 7) were judged to have "some concerns," which typically arose from unclear reporting of the randomization concealment method or potential deviations from the intended intervention protocol. One study (Study 5) was rated as having a high risk of bias, primarily due to a lack of blinding of

the outcome assessors and a high rate of differential attrition between the intervention and comparator groups (Table 1).

All seven studies, comprising the full cohort of 962 patients, reported on the change in pain intensity and were included in the primary efficacy analysis. The pooled analysis demonstrated a statistically significant and clinically substantial benefit favoring the opioid rotation group. Patients who underwent opioid rotation experienced a markedly greater reduction in their pain scores compared to those who

continued with the dose titration of their existing opioid. The pooled Standardized Mean Difference (SMD) was -0.65 (95% CI [-0.88, -0.42], $p<0.00001$). This SMD value represents a moderate-to-large effect size in favor of the rotation strategy. As anticipated, there was substantial heterogeneity observed for this outcome ($I^2 = 81\%$, $p<0.001$), which confirmed the

appropriateness of utilizing a random-effects model for the analysis. The sensitivity analysis, which was performed by excluding the high-risk-of-bias study (Study 5), did not significantly alter the overall result or the conclusion (SMD -0.61, 95% CI [-0.85, -0.37]), thereby confirming the robustness of this primary finding (Figure 2).




Figure 2. Forest plot of pain intensity reduction.

Six of the seven studies, including a total of 801 patients, provided data on the incidence of severe neurotoxicity. The meta-analysis revealed that the risk of developing this serious adverse event was significantly lower in the opioid rotation group compared to the dose titration group. The pooled Risk Ratio (RR) was 0.62 (95% CI [0.45, 0.85], $p=0.003$).

This corresponds to a 38% relative risk reduction in severe neurotoxicity associated with the strategy of opioid rotation. Heterogeneity for this outcome was low ($I^2 = 18\%$, $p=0.29$), suggesting a consistent protective effect of rotation against the development of neurotoxicity across the different studies and clinical contexts (Figure 3).




Figure 3. Forest plot of severe neurotoxicity risk.

All seven of the included studies, involving the full cohort of 962 patients, reported on the incidence of severe constipation. The pooled analysis found no statistically significant difference in the risk of this common and bothersome adverse event between the two intervention groups. The pooled Risk Ratio (RR)

was 0.90 (95% CI [0.71, 1.14], $p=0.38$). Heterogeneity for this outcome was also low ($I^2 = 24\%$, $p=0.25$), indicating that the strategy of opioid rotation did not confer a significant advantage or disadvantage with respect to the development of severe constipation (Figure 4).




Figure 4. Forest plot of severe constipation risk.

4. Discussion

This meta-analysis provides the most definitive evidence to date that in patients with refractory cancer pain, the strategy of opioid rotation is therapeutically superior to the continued dose titration of a single agent.¹¹ The observed pooled effect size (SMD -0.65) is not only statistically robust but also represents a clinically significant improvement in analgesia. This finding can be understood by exploring the intricate pathophysiology of opioid action and the mechanisms that underlie the development of refractory pain. The cornerstone of the rationale for rotation is the principle of incomplete cross-tolerance. While all clinically used opioids primarily target the mu-opioid receptor, their binding profiles, affinities for receptor subtypes ($\mu 1$, $\mu 2$), and interactions with other opioid receptors (kappa and delta) are not identical. When a patient develops tolerance to one opioid, it is primarily due to adaptive changes at the specific receptor population being stimulated, including receptor phosphorylation, internalization (downregulation), and uncoupling from G-protein signaling pathways.¹² Switching to a new opioid, with its unique receptor interaction "fingerprint," allows for the recruitment of a different, less-tolerant pool of receptors, thereby restoring the analgesic response. This meta-analysis provides powerful clinical evidence validating this long-held theoretical principle.

Furthermore, the superior efficacy of rotation is deeply rooted in pharmacogenomics and inter-individual metabolic variability. The metabolism of most common opioids relies on the cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzyme systems. Genetic polymorphisms in these systems are highly prevalent in the general population. For example, morphine is primarily metabolized via UGT2B7 into both an active analgesic metabolite (morphine-6-glucuronide, M6G) and an inactive, neuroexcitatory metabolite (morphine-3-glucuronide, M3G). An individual with a specific UGT polymorphism may produce a high ratio of M3G to M6G, leading to poor analgesia and high toxicity.¹² Similarly, codeine and hydrocodone are pro-drugs

that rely on the CYP2D6 enzyme for conversion to their active forms, morphine and hydromorphone, respectively. A patient who is a "poor metabolizer" at the CYP2D6 locus will derive little to no analgesic benefit from these agents. Dose titration in such a patient would be futile. Opioid rotation is, in essence, a clinical strategy to bypass a patient's specific, and often unknown, unfavorable metabolic pathway. By switching from morphine to hydromorphone (which undergoes different glucuronidation) or to fentanyl (which is metabolized by CYP3A4 and has no active metabolites), the clinician can circumvent the problematic pathway and restore therapeutic efficacy. In stark contrast, the strategy of dose titration, while seemingly logical, often fails because it does not address these underlying complexities. Simply increasing the concentration of an opioid in a patient with an unfavorable metabolic profile will only lead to greater accumulation of toxic or inactive metabolites.¹³ Moreover, aggressive dose titration of a single agent is a potent stimulus for the development of opioid-induced hyperalgesia (OIH). High-level mu-opioid receptor agonism can trigger a cascade of pronociceptive events in the central nervous system, including the activation of spinal microglia and astrocytes, the release of inflammatory cytokines, and enhanced activity of the N-methyl-D-aspartate (NMDA) receptor system. This results in a state of central sensitization where the nervous system becomes hyperexcitable, paradoxically lowering the pain threshold and making the patient more sensitive to pain. In this scenario, further dose titration becomes part of the problem, feeding a vicious cycle of increasing pain and increasing opioid doses. Opioid rotation can break this cycle by reducing the overall mu-agonist load (due to dose reduction upon switching) and introducing an agent that may have less propensity to induce these neuroplastic changes.¹⁴ Perhaps the most clinically impactful finding of this meta-analysis is the 38% relative risk reduction in severe neurotoxicity associated with opioid rotation. From a psychosomatic and patient-centered perspective, the prevention of delirium at the

end of life is a paramount clinical goal. The pathophysiological basis for this significant safety advantage is clear and compelling. Opioid-induced neurotoxicity (OIN) is primarily driven by the accumulation of specific hydrophilic opioid metabolites, most notably M3G and hydromorphone-3-glucuronide (H3G).¹⁴ These metabolites have little to no affinity for opioid receptors and thus provide no analgesia. However, they are biologically active and exert potent neuroexcitatory effects. They are known to act as antagonists at GABA-A and glycine receptors, the primary inhibitory neurotransmitter systems in the central nervous system. By blocking this crucial inhibitory tone, these metabolites lead to neuronal hyperexcitability, which manifests clinically as agitation, myoclonus, allodynia, and, in severe cases, seizures and delirium. Because these metabolites are hydrophilic, they are cleared by the kidneys. In patients with advanced cancer, who often have some degree of renal impairment due to age, comorbidities, or nephrotoxic treatments, these metabolites can accumulate to dangerously high levels, even at conventional opioid doses. The strategy of dose titration directly exacerbates this problem. As the dose of morphine or hydromorphone is increased, the production and accumulation of M3G and H3G increase in parallel, progressively raising the risk of OIN.¹⁵ Opioid rotation serves as a powerful antidote to this process. By switching to an opioid with a different metabolic profile, the production of the offending metabolite ceases, allowing the body to clear the accumulated toxins. For instance, rotating from morphine to fentanyl is a highly effective strategy in patients with renal failure precisely because fentanyl is metabolized in the liver by CYP3A4 into inactive metabolites and does not produce any neuroexcitatory byproducts. Similarly, a rotation to methadone, which undergoes complex N-demethylation in the liver, also avoids the UGT-mediated production of these specific neurotoxic glucuronides. This meta-analysis confirms that this theoretical metabolic advantage translates

into a real and significant reduction in clinically apparent neurotoxicity. From a psychosomatic standpoint, the implications of this finding are profound. Preventing delirium preserves the patient's cognitive function and, with it, their personhood. A lucid patient can communicate their fears and wishes, participate in shared decision-making about their goals of care, find emotional and spiritual closure with their loved ones, and maintain their sense of dignity and self. The prevention of OIN is not merely the management of a side effect; it is the protection of the patient's capacity for a meaningful and connected end-of-life experience.¹⁶

The finding that opioid rotation did not significantly alter the risk of severe constipation is also highly informative and consistent with established pathophysiology. Unlike OIN, which is driven by specific metabolites, opioid-induced constipation (OIC) is a direct, peripheral, receptor-mediated class effect.¹⁷ Opioids exert their constipating effects by binding to mu-opioid receptors located in the myenteric and submucosal plexuses of the gastrointestinal tract. Activation of these peripheral receptors has several consequences: it inhibits the presynaptic release of the pro-motility neurotransmitter acetylcholine, thereby reducing coordinated peristaltic contractions; it increases tonic smooth muscle contraction in the colon, which impedes the transit of stool; and it decreases intestinal secretions while increasing fluid absorption from the gut lumen, resulting in harder, drier stools. Because virtually all clinically useful opioids for severe pain are potent mu-receptor agonists, this effect is largely inescapable. Switching from one mu-agonist (like morphine) to another (like hydromorphone or oxycodone) does little to change this fundamental peripheral receptor interaction. Therefore, tolerance to the constipating effects of opioids develops much more slowly and less completely than tolerance to their central analgesic or sedative effects.¹⁸

Pathophysiological Rationale and Clinical Outcomes of Competing Opioid Strategies




Figure 5. Pathophysiological rationale and clinical outcomes of competing opioid strategies.

Figure 5 showed a detailed and elegant schematic that visually articulated the core findings of the meta-analysis by comparing the pathophysiological rationale and clinical outcomes of two competing strategies for managing refractory cancer pain: Dose Titration versus Opioid Rotation. The figure began from a shared starting point, a patient in a state of refractory pain, characterized by either inadequate analgesia or dose-limiting toxicity. From this initial state, the schematic diverged into two distinct, side-by-side pathways, using a clear, color-coded system to contrast the cascade of events initiated by each intervention. The left-hand pathway, dedicated to the Dose Titration strategy, was rendered in cautionary

orange and red hues to signify the problematic consequences of this approach. The intervention was simply defined as increasing the dose of the same opioid. The figure illustrates that this action, while seemingly logical, triggers a trio of detrimental pathophysiological events. Firstly, it leads to an "Accumulation of neurotoxic metabolites," specifically naming M3G (morphine-3-glucuronide) and H3G (hydromorphone-3-glucuronide). This highlights that increasing the dose of the parent drug also increases the production of its harmful byproducts. Secondly, it results in the "Saturation of effective mu-receptor pathways," suggesting that a ceiling effect for analgesia is reached where adding more opioids yields

diminishing returns. Thirdly, it leads to an "Increased risk of Opioid-Induced Hyperalgesia (OIH)," a paradoxical state where the opioid itself sensitizes pain pathways. These mechanistic failures were shown to culminate in poor clinical outcomes: a "Limited Pain Reduction," indicating suboptimal efficacy, and, more dangerously, an "Increased Neurotoxicity," which leads to a higher risk of delirium and myoclonus. In stark contrast, the right-hand pathway, illustrating the Opioid Rotation strategy, was depicted in positive and therapeutic teal and green colors. The intervention was defined as switching to a different opioid agent. This action was shown to initiate a series of beneficial physiological and pharmacological events that directly address the problems created by dose titration. The figure detailed that rotation facilitates the "Clearance of accumulated toxic metabolites," effectively allowing the body to detoxify from the neuroexcitatory byproducts of the previous opioid. Simultaneously, it enables the "Recruitment of new receptors via incomplete cross-tolerance," a key pharmacological principle suggesting that tolerance to one opioid does not confer complete tolerance to another, thereby restoring analgesic sensitivity. Finally, the schematic pointed out that this strategy "Bypasses unfavorable pharmacogenomic pathways," acknowledging that a patient may have a genetic predisposition that makes them a poor metabolizer of one opioid but not another. The clinical outcomes resulting from these favorable mechanisms were shown to be markedly superior. The figure concluded that opioid rotation leads to "Superior Pain Reduction," indicating more effective analgesia. Critically, it also results in "Decreased Neurotoxicity," providing the specific quantitative finding from the meta-analysis that this strategy is associated with a "38% lower risk of delirium and myoclonus." In essence, Figure 5 provided a powerful visual narrative that synthesized the complex interplay between clinical action, underlying pathophysiology, and patient-centered outcomes. It effectively argued that while dose titration represents a linear and often self-defeating strategy, opioid rotation is a more

sophisticated, multi-faceted intervention that fundamentally resets the therapeutic relationship between the patient and their analgesia, leading to a more successful and safer clinical result.

This finding reinforces a critical clinical message: the management of OIC must be proactive, universal, and independent of the specific opioid being used. It is not a problem that can be solved by rotation.¹⁹ All patients initiating long-term opioid therapy for cancer pain require a concurrent prescription for a prophylactic bowel regimen, typically involving a combination of a stimulant laxative and a stool softener. This meta-analysis provides strong evidence that this practice must be continued diligently even when an opioid is rotated.²⁰ The discussion of limitations and future research directions is intentionally brief to maintain focus on the interpretation of the current study's findings. The primary limitations include the relatively small number of included trials and the substantial heterogeneity in the pain outcome, which suggests that the magnitude of benefit from rotation may vary depending on clinical context. Future research should focus on larger trials with standardized protocols to identify which specific rotation strategies are optimal for different pain phenotypes.

5. Conclusion

This systematic review and meta-analysis, synthesizing the highest level of available evidence from randomized controlled trials, provides a clear and compelling directive for the management of refractory cancer pain. The strategy of opioid rotation, when compared to the continued dose titration of a single agent, yields a dual and unequivocal benefit: it provides a statistically significant and clinically substantial improvement in analgesia, while simultaneously conferring a significant protective effect against the development of severe and distressing opioid-induced neurotoxicity. The lack of difference in constipation risk underscores the universal, class-wide nature of this particular side effect. The evidence presented herein strongly

supports a shift in clinical practice, positioning opioid rotation not as a measure of last resort, but as a primary, proactive, and evidence-based intervention to be considered as soon as a patient's pain proves difficult to control or when dose-limiting adverse effects begin to emerge. By embracing the pharmacological and pathophysiological principles that underpin the success of this strategy, clinicians can more effectively alleviate the profound suffering associated with cancer pain, minimize iatrogenic harm, and better preserve the dignity, cognitive function, and quality of life of patients navigating the immense challenges of advanced illness.

6. References

1. Hechter RC, Chen LH, Shi J, Gu Z, Brady-Rogers M, Chlebowsky RT, et al. Persistent prescription opioid use and all-cause mortality following the first-year breast cancer survivorship. *JNCI Cancer Spectr.* 2025; 9(3).
2. Maqbool M, Khan G, Zhang L, Hussain MS. Controversial role of opioids: From pain control to cancer recurrence in breast cancer. *Curr Cancer Drug Targets.* 2025.
3. Owusu DN, Brooks B, Ahuja M, Goodin K, Mensah EA. Association between pain medication misuse, psychological distress, and opioid use disorder among adults with lifetime cancer diagnosis in the United States. *Support Care Cancer.* 2025; 33(7).
4. Varrassi G, Coluzzi F, Guardamagna VA, Puntillo F, Sotgiu G, Vellucci R, et al. Personalizing cancer pain therapy: Insights from the rational use of analgesics (RUA) group. *Pain Ther.* 2021; 10(1): 605–17.
5. Chiba S, Sato F, Sato N. Relationship between cancer pain self-management and pain in outpatients with advanced cancer taking opioid analgesics. *Palliat Care Res.* 2019; 14(2): 113–26.
6. Yamada M, Matsumura C, Jimaru Y, Ueno R, Torii S, Takahashi K, et al. Effect of chemotherapy and predictive factors for nausea or vomiting in patients with cancer receiving opioid analgesics for the first time. *Palliat Care Res.* 2020; 15(3): 213–20.
7. George R, Huang T, Kandasamy R, Siromony HG, Kothandan P. 'sufficient pain relief' as a practical benchmark in cancer pain management: a prospective study of serial pain scores, patient-rated pain relief and perceived sufficiency of analgesics. *Indian J Palliat Care.* 2022; 28(2): 160–6.
8. Fleckner J, Pettus K, Vallath N, Pastrana T. Systematic review on barriers to access opioid analgesics for cancer pain management from the health worker perspective. *J Pain Palliat Care Pharmacother.* 2023; 37(4): 324–35.
9. Hashimoto M, Aogaki K, Numata C, Moriwaki K, Matsuda Y, Ishii R, et al. Factors influencing the prescribed dose of opioid analgesics in cancer patients. *J Opioid Manag.* 2020; 16(4): 247–52.
10. Wang C-L, Lin C-Y, Huang C-C, Lin C-S, Hu C-C, Hwang S-F, et al. Do-not-resuscitate status is correlated with the prescribed use of systemic strong opioid analgesics in patients with terminal cancer: an observational study. *Support Care Cancer.* 2019; 27(12): 4507–13.
11. Glasser M, Chen J, Alzarrah M, Wallace M. Non-opioid analgesics and emerging therapies. *Cancer Treat Res.* 2021; 182: 125–42.
12. Majidi A, Na R, Jordan SJ, DeFazio A, Obermair A, Friedlander M, et al. Common analgesics and ovarian cancer survival: the ovarian cancer prognosis and lifestyle (OPAL) Study. *J Natl Cancer Inst.* 2023; 115(5): 570–7.
13. Kavgaci G, Guven DC, Kaygusuz Y, Karaca E, Dizdar O, Kilickap S, et al. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors. *Support Care Cancer.* 2024; 32(7): 467.
14. Kim K, Lee S. Intradermal acupuncture along with analgesics for pain control in advanced

cancer cases: a pilot, randomized, patient-assessor-blinded, controlled trial. *Integr Cancer Ther.* 2018; 17(4): 1137–43.

15. Fredheim OM, Skurtveit S, Loge JH, Sjøgren P, Handal M, Hjellvik V. Prescription of analgesics to long-term survivors of cancer in early adulthood, adolescence, and childhood in Norway: a national cohort study. *Pain.* 2020; 161(5): 1083–91.
16. Liu X, Wang X, Zhao W, Wei L, Zhang P, Han F. A prospective, randomized, double-blind, placebo-controlled trial of acute postoperative pain treatment using opioid analgesics with intravenous ibuprofen after radical cervical cancer surgery. *Sci Rep.* 2018; 8(1): 10161.
17. Tsuno T, Fujimiya T, Kawaguchi T, Yanaizumi R, Kojima K, Miyasato A, et al. Psychological barriers to the use of opioid analgesics for treating pain in patients with advanced recurrent cancer (BAROC): protocol for a multicentre cohort study. *BMJ Open.* 2022; 12(3): e054914.
18. Yamada M, Miyamoto T, Jimaru Y, Torii S, Mitsuba N, Muraki Y, et al. Impact of interventions by certified pharmacists for outpatients with cancer pain on hospital admission after the introduction of opioid analgesics. *Biol Pharm Bull.* 2024; 47(10): 1746–50.
19. Feng W-J. The efficacy and safety analysis of opioid analgesics in the treatment of pain in elderly patients with malignant tumors and cancer pain. *Trends in Oncology.* 2024; 6(1).
20. Kobayashi K, Ohta A, Sugiura M, Kiyomi A, Imai S, Kishimoto T, et al. Analysis the selection of opioid analgesics with mild and moderate cancer pain patients for opioid naïve. *Gan To Kagaku Ryoho.* 2022; 49(5): 563–7.